Piper Sandler Boosts Bausch Health Companies (NYSE:BHC) Price Target to $9.00

Bausch Health Companies (NYSE:BHC) had its price objective hoisted by analysts at Piper Sandler from $7.00 to $9.00 in a research note issued to investors on Monday, BayStreet.CA reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 2.27% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Jefferies Financial Group lowered their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Finally, Royal Bank of Canada decreased their price objective on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 23rd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus target price of $11.33.

Bausch Health Companies Price Performance

Shares of BHC stock traded up $0.09 on Monday, hitting $8.80. The stock had a trading volume of 629,218 shares, compared to its average volume of 2,756,339. The firm has a market capitalization of $3.22 billion, a P/E ratio of -5.43 and a beta of 0.85. Bausch Health Companies has a 1 year low of $5.57 and a 1 year high of $11.46. The company’s 50 day moving average price is $9.30 and its 200-day moving average price is $8.18.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.02 EPS. On average, equities analysts forecast that Bausch Health Companies will post 3.95 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Principal Securities Inc. acquired a new stake in Bausch Health Companies during the 4th quarter valued at $31,000. Salem Investment Counselors Inc. purchased a new position in shares of Bausch Health Companies during the 1st quarter valued at $32,000. Tower Research Capital LLC TRC grew its holdings in shares of Bausch Health Companies by 283.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock valued at $55,000 after acquiring an additional 5,112 shares in the last quarter. Bfsg LLC bought a new stake in Bausch Health Companies in the fourth quarter worth $63,000. Finally, Ausdal Financial Partners Inc. bought a new stake in Bausch Health Companies in the third quarter worth $86,000. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.